Palatin Technologies is a biopharmaceutical company, developing targeted, receptor-specific peptide therapeutics for the treatment of various diseases. The Company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder. Its drug development programs also include melanocortin peptide system program, including PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation.